A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.
AXL
BTCE
BiTe
Bispecific T cell engager
CD3
Cancer
Immunotherapy
Ovarian cancer
Pronectins
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
04 05 2023
04 05 2023
Historique:
received:
20
02
2023
accepted:
01
04
2023
medline:
8
5
2023
pubmed:
5
5
2023
entrez:
4
5
2023
Statut:
epublish
Résumé
Pronectins™ are a new class of fibronectin-3-domain 14th-derived (14Fn3) antibody mimics that can be engineered as bispecific T cell engager (BTCE) to redirect immune effector cells against cancer. We describe here the in vitro and in vivo activity of a Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) against Epithelial Ovarian Cancer (EOC). pAXLxCD3ε T-cell mediated cytotoxicity was evaluated by flow cytometry and bioluminescence. pAXLxCD3ε mediated T-cell infiltration, activation and proliferation were assessed by immunofluorescence microscopy and by flow cytometry. Activity of pAXLxCD3ε was also investigated in combination with poly-ADP ribose polymerase inhibitors (PARPi). In vivo antitumor activity of pAXLxCD3ε was evaluated in immunocompromised (NSG) mice bearing intraperitoneal or subcutaneous EOC xenografts and immunologically reconstituted with human peripheral blood mononuclear cells (PBMC). pAXLxCD3ε induced dose-dependent cytotoxicity by activation of T lymphocytes against EOC cells, regardless of their histologic origin. The addition of PARPi to cell cultures enhanced pAXLxCD3ε cytotoxicity. Importantly, in vivo, pAXLxCD3ε was highly effective against EOC xenografts in two different NSG mouse models, by inhibiting the growth of tumor cells in ascites and subcutaneous xenografts. This effect translated into a significantly prolonged survival of treated animals. pAXLxCD3ε is an active therapeutics against EOC cells providing a rational for its development as a novel agent in this still incurable disease. The preclinical validation of a first-in-class agent opens the way to the development of a new 14Fn3-based scaffold platform for the generation of innovative immune therapeutics against cancer.
Sections du résumé
BACKGROUND
Pronectins™ are a new class of fibronectin-3-domain 14th-derived (14Fn3) antibody mimics that can be engineered as bispecific T cell engager (BTCE) to redirect immune effector cells against cancer. We describe here the in vitro and in vivo activity of a Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) against Epithelial Ovarian Cancer (EOC).
METHODS
pAXLxCD3ε T-cell mediated cytotoxicity was evaluated by flow cytometry and bioluminescence. pAXLxCD3ε mediated T-cell infiltration, activation and proliferation were assessed by immunofluorescence microscopy and by flow cytometry. Activity of pAXLxCD3ε was also investigated in combination with poly-ADP ribose polymerase inhibitors (PARPi). In vivo antitumor activity of pAXLxCD3ε was evaluated in immunocompromised (NSG) mice bearing intraperitoneal or subcutaneous EOC xenografts and immunologically reconstituted with human peripheral blood mononuclear cells (PBMC).
RESULTS
pAXLxCD3ε induced dose-dependent cytotoxicity by activation of T lymphocytes against EOC cells, regardless of their histologic origin. The addition of PARPi to cell cultures enhanced pAXLxCD3ε cytotoxicity. Importantly, in vivo, pAXLxCD3ε was highly effective against EOC xenografts in two different NSG mouse models, by inhibiting the growth of tumor cells in ascites and subcutaneous xenografts. This effect translated into a significantly prolonged survival of treated animals.
CONCLUSION
pAXLxCD3ε is an active therapeutics against EOC cells providing a rational for its development as a novel agent in this still incurable disease. The preclinical validation of a first-in-class agent opens the way to the development of a new 14Fn3-based scaffold platform for the generation of innovative immune therapeutics against cancer.
Identifiants
pubmed: 37143061
doi: 10.1186/s12967-023-04101-x
pii: 10.1186/s12967-023-04101-x
pmc: PMC10161629
doi:
Substances chimiques
Antibodies, Bispecific
0
CD3 Complex
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
301Informations de copyright
© 2023. The Author(s).
Références
GEN Biotechnol. 2023 Feb 1;2(1):43-56
pubmed: 36873811
J Mol Biol. 2007 May 11;368(4):1024-41
pubmed: 17382960
J Transl Med. 2021 Oct 7;19(1):415
pubmed: 34620163
Acta Pharmacol Sin. 2021 Jul;42(7):1180-1189
pubmed: 33149145
J Transl Med. 2022 Feb 10;20(1):82
pubmed: 35144648
Biomedicines. 2022 Dec 08;10(12):
pubmed: 36551940
Br J Haematol. 2008 Nov;143(4):520-31
pubmed: 18986388
Cancer Chemother Pharmacol. 2009 Oct;64(5):1009-20
pubmed: 19263052
Cancers (Basel). 2021 Aug 29;13(17):
pubmed: 34503175
Cancer Res. 2010 Oct 1;70(19):7570-9
pubmed: 20858715
Cancer Res. 2019 Jan 15;79(2):311-319
pubmed: 30482774
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33597219
Cancers (Basel). 2020 Jul 09;12(7):
pubmed: 32660000
J Exp Clin Cancer Res. 2020 May 12;39(1):87
pubmed: 32398042
J Transl Med. 2013 Jun 13;11:147
pubmed: 23763830
J Mol Biol. 2012 Jan 13;415(2):393-405
pubmed: 22198408
N Engl J Med. 2017 Mar 2;376(9):836-847
pubmed: 28249141
J Transl Med. 2017 Jun 19;15(1):142
pubmed: 28629381
Fibrogenesis Tissue Repair. 2011 Sep 16;4:21
pubmed: 21923916
Int J Immunopharmacol. 1992 May;14(4):555-63
pubmed: 1521923
Onco Targets Ther. 2018 Jan 23;11:509-519
pubmed: 29416351
Protein Eng Des Sel. 2014 Oct;27(10):419-29
pubmed: 24786107
Int J Mol Sci. 2021 Sep 15;22(18):
pubmed: 34576116
Cancers (Basel). 2021 Jan 14;13(2):
pubmed: 33466732
Clin Transl Sci. 2021 Jan;14(1):113-119
pubmed: 33089968
J Mol Biol. 1998 Dec 11;284(4):1141-51
pubmed: 9837732
MAbs. 2010 Mar-Apr;2(2):129-36
pubmed: 20190561
Cancers (Basel). 2021 Mar 25;13(7):
pubmed: 33806258
J Exp Clin Cancer Res. 2019 Aug 14;38(1):355
pubmed: 31412896
Swiss Med Wkly. 2017 Nov 29;147:w14545
pubmed: 29185244
Cancer Discov. 2018 Aug;8(8):924-934
pubmed: 30012854
Cells. 2020 Mar 04;9(3):
pubmed: 32143310
Front Oncol. 2021 Oct 28;11:756225
pubmed: 34778071
J Exp Clin Cancer Res. 2015 Oct 17;34:123
pubmed: 26474755
Mol Ther Nucleic Acids. 2017 Dec 15;9:251-262
pubmed: 29246304
Cancers (Basel). 2022 Jun 11;14(12):
pubmed: 35740552
J Transl Med. 2020 Nov 19;18(1):439
pubmed: 33213473
J Transl Med. 2014 Dec 13;12:347
pubmed: 25496493
Front Immunol. 2022 Oct 28;13:1035276
pubmed: 36389699
J Hematol Oncol. 2021 May 3;14(1):75
pubmed: 33941237
Int J Cancer. 2020 Nov 15;147(10):2658-2668
pubmed: 32383203
Mol Cancer. 2019 Nov 4;18(1):153
pubmed: 31684958
High Throughput. 2018 Dec 18;7(4):
pubmed: 30567415
J Transl Med. 2020 Mar 23;18(1):134
pubmed: 32293460